Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study
Background Siponimod is a sphingosine 1-phosphate receptor modulator approved for active secondary progressive multiple sclerosis (aSPMS) in most countries; however, phase 3 EXPAND study data are from an SPMS population with/without disease activity. A need exists to characterize efficacy/safety of...
Gespeichert in:
| Veröffentlicht in: | Journal of neurology Jg. 269; H. 9; S. 5093 - 5104 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.09.2022
Springer Nature B.V |
| Schlagworte: | |
| ISSN: | 0340-5354, 1432-1459, 1432-1459 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Background
Siponimod is a sphingosine 1-phosphate receptor modulator approved for active secondary progressive multiple sclerosis (aSPMS) in most countries; however, phase 3 EXPAND study data are from an SPMS population with/without disease activity. A need exists to characterize efficacy/safety of siponimod in aSPMS.
Methods
Post hoc analysis of participants with aSPMS (≥ 1 relapse in 2 years before study and/or ≥ 1 T1 gadolinium-enhancing [Gd +] magnetic resonance imaging [MRI] lesions at baseline) receiving oral siponimod (2 mg/day) or placebo for up to 3 years in EXPAND. Endpoints: 3-month/6-month confirmed disability progression (3mCDP/6mCDP); 3-month confirmed ≥ 20% worsening in Timed 25-Foot Walk (T25FW); 6-month confirmed improvement/worsening in Symbol Digit Modalities Test (SDMT) scores (≥ 4-point change); T2 lesion volume (T2LV) change from baseline; number of T1 Gd + lesions baseline–month 24; number of new/enlarging (N/E) T2 lesions over all visits.
Results
Data from 779 participants with aSPMS were analysed. Siponimod reduced risk of 3mCDP/6mCDP vs placebo (by 31%/37%, respectively;
p
< 0.01); there was no significant effect on T25FW. Siponimod increased likelihood of 6-month confirmed SDMT improvement vs placebo (by 62%;
p
= 0.007) and reduced risk of 6-month confirmed SDMT worsening (by 27%;
p
= 0.060). Siponimod was associated with less increase in T2LV (1316.3 vs 13.3 mm
3
;
p
< 0.0001), and fewer T1 Gd + and N/E T2 lesions than placebo (85% and 80% reductions, respectively;
p
< 0.0001).
Conclusions
In aSPMS, siponimod reduced risk of disability progression and was associated with benefits on cognition and MRI outcomes vs placebo.
Trial registration
ClinicalTrials.gov number
: NCT01665144. |
|---|---|
| AbstractList | Siponimod is a sphingosine 1-phosphate receptor modulator approved for active secondary progressive multiple sclerosis (aSPMS) in most countries; however, phase 3 EXPAND study data are from an SPMS population with/without disease activity. A need exists to characterize efficacy/safety of siponimod in aSPMS.
Post hoc analysis of participants with aSPMS (≥ 1 relapse in 2 years before study and/or ≥ 1 T1 gadolinium-enhancing [Gd +] magnetic resonance imaging [MRI] lesions at baseline) receiving oral siponimod (2 mg/day) or placebo for up to 3 years in EXPAND.
3-month/6-month confirmed disability progression (3mCDP/6mCDP); 3-month confirmed ≥ 20% worsening in Timed 25-Foot Walk (T25FW); 6-month confirmed improvement/worsening in Symbol Digit Modalities Test (SDMT) scores (≥ 4-point change); T2 lesion volume (T2LV) change from baseline; number of T1 Gd + lesions baseline-month 24; number of new/enlarging (N/E) T2 lesions over all visits.
Data from 779 participants with aSPMS were analysed. Siponimod reduced risk of 3mCDP/6mCDP vs placebo (by 31%/37%, respectively; p < 0.01); there was no significant effect on T25FW. Siponimod increased likelihood of 6-month confirmed SDMT improvement vs placebo (by 62%; p = 0.007) and reduced risk of 6-month confirmed SDMT worsening (by 27%; p = 0.060). Siponimod was associated with less increase in T2LV (1316.3 vs 13.3 mm
; p < 0.0001), and fewer T1 Gd + and N/E T2 lesions than placebo (85% and 80% reductions, respectively; p < 0.0001).
In aSPMS, siponimod reduced risk of disability progression and was associated with benefits on cognition and MRI outcomes vs placebo.
ClinicalTrials.gov number: NCT01665144. Siponimod is a sphingosine 1-phosphate receptor modulator approved for active secondary progressive multiple sclerosis (aSPMS) in most countries; however, phase 3 EXPAND study data are from an SPMS population with/without disease activity. A need exists to characterize efficacy/safety of siponimod in aSPMS.BACKGROUNDSiponimod is a sphingosine 1-phosphate receptor modulator approved for active secondary progressive multiple sclerosis (aSPMS) in most countries; however, phase 3 EXPAND study data are from an SPMS population with/without disease activity. A need exists to characterize efficacy/safety of siponimod in aSPMS.Post hoc analysis of participants with aSPMS (≥ 1 relapse in 2 years before study and/or ≥ 1 T1 gadolinium-enhancing [Gd +] magnetic resonance imaging [MRI] lesions at baseline) receiving oral siponimod (2 mg/day) or placebo for up to 3 years in EXPAND.METHODSPost hoc analysis of participants with aSPMS (≥ 1 relapse in 2 years before study and/or ≥ 1 T1 gadolinium-enhancing [Gd +] magnetic resonance imaging [MRI] lesions at baseline) receiving oral siponimod (2 mg/day) or placebo for up to 3 years in EXPAND.3-month/6-month confirmed disability progression (3mCDP/6mCDP); 3-month confirmed ≥ 20% worsening in Timed 25-Foot Walk (T25FW); 6-month confirmed improvement/worsening in Symbol Digit Modalities Test (SDMT) scores (≥ 4-point change); T2 lesion volume (T2LV) change from baseline; number of T1 Gd + lesions baseline-month 24; number of new/enlarging (N/E) T2 lesions over all visits.ENDPOINTS3-month/6-month confirmed disability progression (3mCDP/6mCDP); 3-month confirmed ≥ 20% worsening in Timed 25-Foot Walk (T25FW); 6-month confirmed improvement/worsening in Symbol Digit Modalities Test (SDMT) scores (≥ 4-point change); T2 lesion volume (T2LV) change from baseline; number of T1 Gd + lesions baseline-month 24; number of new/enlarging (N/E) T2 lesions over all visits.Data from 779 participants with aSPMS were analysed. Siponimod reduced risk of 3mCDP/6mCDP vs placebo (by 31%/37%, respectively; p < 0.01); there was no significant effect on T25FW. Siponimod increased likelihood of 6-month confirmed SDMT improvement vs placebo (by 62%; p = 0.007) and reduced risk of 6-month confirmed SDMT worsening (by 27%; p = 0.060). Siponimod was associated with less increase in T2LV (1316.3 vs 13.3 mm3; p < 0.0001), and fewer T1 Gd + and N/E T2 lesions than placebo (85% and 80% reductions, respectively; p < 0.0001).RESULTSData from 779 participants with aSPMS were analysed. Siponimod reduced risk of 3mCDP/6mCDP vs placebo (by 31%/37%, respectively; p < 0.01); there was no significant effect on T25FW. Siponimod increased likelihood of 6-month confirmed SDMT improvement vs placebo (by 62%; p = 0.007) and reduced risk of 6-month confirmed SDMT worsening (by 27%; p = 0.060). Siponimod was associated with less increase in T2LV (1316.3 vs 13.3 mm3; p < 0.0001), and fewer T1 Gd + and N/E T2 lesions than placebo (85% and 80% reductions, respectively; p < 0.0001).In aSPMS, siponimod reduced risk of disability progression and was associated with benefits on cognition and MRI outcomes vs placebo.CONCLUSIONSIn aSPMS, siponimod reduced risk of disability progression and was associated with benefits on cognition and MRI outcomes vs placebo.ClinicalTrials.gov number: NCT01665144.TRIAL REGISTRATIONClinicalTrials.gov number: NCT01665144. Background Siponimod is a sphingosine 1-phosphate receptor modulator approved for active secondary progressive multiple sclerosis (aSPMS) in most countries; however, phase 3 EXPAND study data are from an SPMS population with/without disease activity. A need exists to characterize efficacy/safety of siponimod in aSPMS. Methods Post hoc analysis of participants with aSPMS (≥ 1 relapse in 2 years before study and/or ≥ 1 T1 gadolinium-enhancing [Gd +] magnetic resonance imaging [MRI] lesions at baseline) receiving oral siponimod (2 mg/day) or placebo for up to 3 years in EXPAND. Endpoints: 3-month/6-month confirmed disability progression (3mCDP/6mCDP); 3-month confirmed ≥ 20% worsening in Timed 25-Foot Walk (T25FW); 6-month confirmed improvement/worsening in Symbol Digit Modalities Test (SDMT) scores (≥ 4-point change); T2 lesion volume (T2LV) change from baseline; number of T1 Gd + lesions baseline–month 24; number of new/enlarging (N/E) T2 lesions over all visits. Results Data from 779 participants with aSPMS were analysed. Siponimod reduced risk of 3mCDP/6mCDP vs placebo (by 31%/37%, respectively; p < 0.01); there was no significant effect on T25FW. Siponimod increased likelihood of 6-month confirmed SDMT improvement vs placebo (by 62%; p = 0.007) and reduced risk of 6-month confirmed SDMT worsening (by 27%; p = 0.060). Siponimod was associated with less increase in T2LV (1316.3 vs 13.3 mm 3 ; p < 0.0001), and fewer T1 Gd + and N/E T2 lesions than placebo (85% and 80% reductions, respectively; p < 0.0001). Conclusions In aSPMS, siponimod reduced risk of disability progression and was associated with benefits on cognition and MRI outcomes vs placebo. Trial registration ClinicalTrials.gov number : NCT01665144. BackgroundSiponimod is a sphingosine 1-phosphate receptor modulator approved for active secondary progressive multiple sclerosis (aSPMS) in most countries; however, phase 3 EXPAND study data are from an SPMS population with/without disease activity. A need exists to characterize efficacy/safety of siponimod in aSPMS.MethodsPost hoc analysis of participants with aSPMS (≥ 1 relapse in 2 years before study and/or ≥ 1 T1 gadolinium-enhancing [Gd +] magnetic resonance imaging [MRI] lesions at baseline) receiving oral siponimod (2 mg/day) or placebo for up to 3 years in EXPAND. Endpoints: 3-month/6-month confirmed disability progression (3mCDP/6mCDP); 3-month confirmed ≥ 20% worsening in Timed 25-Foot Walk (T25FW); 6-month confirmed improvement/worsening in Symbol Digit Modalities Test (SDMT) scores (≥ 4-point change); T2 lesion volume (T2LV) change from baseline; number of T1 Gd + lesions baseline–month 24; number of new/enlarging (N/E) T2 lesions over all visits.ResultsData from 779 participants with aSPMS were analysed. Siponimod reduced risk of 3mCDP/6mCDP vs placebo (by 31%/37%, respectively; p < 0.01); there was no significant effect on T25FW. Siponimod increased likelihood of 6-month confirmed SDMT improvement vs placebo (by 62%; p = 0.007) and reduced risk of 6-month confirmed SDMT worsening (by 27%; p = 0.060). Siponimod was associated with less increase in T2LV (1316.3 vs 13.3 mm3; p < 0.0001), and fewer T1 Gd + and N/E T2 lesions than placebo (85% and 80% reductions, respectively; p < 0.0001).ConclusionsIn aSPMS, siponimod reduced risk of disability progression and was associated with benefits on cognition and MRI outcomes vs placebo.Trial registrationClinicalTrials.gov number: NCT01665144. |
| Author | Bar-Or, Amit Fox, Robert J. Benedict, Ralph H. B. Vermersch, Patrick Hach, Thomas Rouyrre, Nicolas Karlsson, Göril Gold, Ralf Dahlke, Frank Kappos, Ludwig Ritter, Shannon Arnold, Douglas L. Kilaru, Ajay Cree, Bruce A. C. Giovannoni, Gavin Penner, Iris-Katharina Piani-Meier, Daniela |
| Author_xml | – sequence: 1 givenname: Ralf surname: Gold fullname: Gold, Ralf email: ralf.gold@ruhr-uni-bochum.de organization: Department of Neurology, St. Josef Hospital and Ruhr University of Bochum – sequence: 2 givenname: Daniela surname: Piani-Meier fullname: Piani-Meier, Daniela organization: Novartis Pharma AG – sequence: 3 givenname: Ludwig surname: Kappos fullname: Kappos, Ludwig organization: Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and Multiple Sclerosis Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital, University of Basel – sequence: 4 givenname: Amit surname: Bar-Or fullname: Bar-Or, Amit organization: Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania – sequence: 5 givenname: Patrick surname: Vermersch fullname: Vermersch, Patrick organization: University of Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise – sequence: 6 givenname: Gavin surname: Giovannoni fullname: Giovannoni, Gavin organization: Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London – sequence: 7 givenname: Robert J. surname: Fox fullname: Fox, Robert J. organization: Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic – sequence: 8 givenname: Douglas L. surname: Arnold fullname: Arnold, Douglas L. organization: NeuroRx Research, Montreal, QC, Canada and Montreal Neurological Institute, McGill University – sequence: 9 givenname: Ralph H. B. surname: Benedict fullname: Benedict, Ralph H. B. organization: Department of Neurology, University at Buffalo – sequence: 10 givenname: Iris-Katharina surname: Penner fullname: Penner, Iris-Katharina organization: Department of Neurology, Inselspital, Bern University Hospital, University of Bern – sequence: 11 givenname: Nicolas surname: Rouyrre fullname: Rouyrre, Nicolas organization: Novartis Pharma AG – sequence: 12 givenname: Ajay surname: Kilaru fullname: Kilaru, Ajay organization: Novartis Pharma AG – sequence: 13 givenname: Göril surname: Karlsson fullname: Karlsson, Göril organization: Novartis Pharma AG – sequence: 14 givenname: Shannon surname: Ritter fullname: Ritter, Shannon organization: Novartis Pharma AG – sequence: 15 givenname: Frank surname: Dahlke fullname: Dahlke, Frank organization: Novartis Pharma AG – sequence: 16 givenname: Thomas surname: Hach fullname: Hach, Thomas organization: Novartis Pharma AG – sequence: 17 givenname: Bruce A. C. surname: Cree fullname: Cree, Bruce A. C. organization: UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35639197$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UstuFDEQtFAQ2QR-gAOyxIXLgO0ej2MOSFEIDykCJEDiZnk9nl1HHnuwPSvtfj1eNuGRQ06Wu6pa1d11go5CDBahp5S8pISIV5mQlvKGMNZQSruu2T1AC9pC_bZcHqEFgZY0HHh7jE5yviaEnFXgEToG3oGkUizQ7qubYnBj7PEm48lrY5cRu4C1KW5jcbYmhl6nLZ5SXCWb8746zr64yVfYeJtidvk11niKueB1NFgH7be1iIcUR1zWFk9rnS0GfPnjy_mntziXud8-Rg8H7bN9cvOeou_vLr9dfGiuPr__eHF-1ZhWtKVhA2gOIDmVA7FLCmTQGiz0rQEjDSMUpBR9nUdoaaQwTPQ9gyXTukJCwyl6c-g7zcvR9saGkrRXU3JjnUtF7dT_SHBrtYobJaED4KQ2eHHTIMWfs81FjS4b670ONs5ZsU4wYKwje-rzO9TrOKe6jsoShFDe1fNU1rN_Hf2xcnuWSjg7EExdbk52UMYVXVzcG3ReUaL2CVCHBKiaAPU7AWpXpeyO9Lb7vSI4iHIlh5VNf23fo_oFDhnE5w |
| CitedBy_id | crossref_primary_10_1016_j_msard_2023_104766 crossref_primary_10_1080_14656566_2023_2178898 crossref_primary_10_3389_fimmu_2025_1543649 crossref_primary_10_1016_j_jneuroim_2024_578330 crossref_primary_10_1080_14656566_2022_2161882 crossref_primary_10_3390_ctn7010002 crossref_primary_10_1016_j_neurot_2025_e00601 crossref_primary_10_1038_s41392_025_02267_y crossref_primary_10_1177_17562864221146836 crossref_primary_10_1007_s00415_025_13217_7 crossref_primary_10_1007_s40120_023_00532_2 |
| Cites_doi | 10.1177/13524585221076717 10.1177/1352458516665496 10.1177/1352458517690821 10.1212/WNL.0000000000011275 10.1177/1352458516674367 10.1155/2015/307175 10.1093/brain/awh721 10.1177/1352458520988637 10.1177/1352458517721355 10.1212/WNL.0000000000000560 10.1523/JNEUROSCI.4645-04.2005 10.1016/S0140-6736(18)30475-6 10.3389/fneur.2017.00643 10.1093/brain/awh641 10.1186/s12974-016-0686-4 10.1111/ene.12715 10.1016/j.tins.2016.02.001 10.1016/S1474-4422(06)70410-0 10.1016/S1474-4422(20)30277-5 10.1177/1352458520971819 10.1038/nature02284 10.1177/1352458516645869 10.1111/j.1476-5381.2012.02061.x 10.1186/s12974-016-0494-x 10.1177/13524585221083194 10.1038/s41598-019-54153-7 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 2022. The Author(s). The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TK 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1007/s00415-022-11166-z |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic ProQuest One Academic Middle East (New) |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1432-1459 |
| EndPage | 5104 |
| ExternalDocumentID | PMC9363350 35639197 10_1007_s00415_022_11166_z |
| Genre | Randomized Controlled Trial Journal Article |
| GrantInformation_xml | – fundername: Ruhr-Universität Bochum (1007) – fundername: Novartis Pharma funderid: http://dx.doi.org/10.13039/100008792 – fundername: NCATS NIH HHS grantid: UL1 TR001412 – fundername: ; |
| GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .55 .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 2.D 203 28- 29L 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3SX 3V. 4.4 406 408 409 40D 40E 53G 5QI 5RE 5VS 67Z 6NX 78A 7X7 88E 8AO 8FI 8FJ 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHIR ADIMF ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFDYV AFEXP AFFNX AFJLC AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGVAE AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI C6C CAG CCPQU COF CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 EPAXT ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK6 WK8 X7M YLTOR Z45 Z7U Z81 Z82 Z83 Z87 Z8O Z8U Z8V Z8W Z91 Z92 ZGI ZMTXR ZOVNA ZXP ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFFHD AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY CGR CUY CVF ECM EIF NPM 7TK 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c474t-2f3a5339519f0eb130faa3e3d4c3c9c2013997d3917a9c97c27dd23b2aa0137a3 |
| IEDL.DBID | 7X7 |
| ISICitedReferencesCount | 12 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000803802100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0340-5354 1432-1459 |
| IngestDate | Tue Nov 04 02:03:16 EST 2025 Fri Sep 05 08:29:39 EDT 2025 Thu Nov 06 12:21:20 EST 2025 Sat Nov 01 14:16:59 EDT 2025 Sat Nov 29 02:48:39 EST 2025 Tue Nov 18 21:02:41 EST 2025 Fri Feb 21 02:46:14 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | EXPAND Active secondary progressive multiple sclerosis Disability progression Cognition Siponimod MRI |
| Language | English |
| License | 2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c474t-2f3a5339519f0eb130faa3e3d4c3c9c2013997d3917a9c97c27dd23b2aa0137a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://link.springer.com/10.1007/s00415-022-11166-z |
| PMID | 35639197 |
| PQID | 2700156432 |
| PQPubID | 47196 |
| PageCount | 12 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9363350 proquest_miscellaneous_2672322600 proquest_journals_2700156432 pubmed_primary_35639197 crossref_citationtrail_10_1007_s00415_022_11166_z crossref_primary_10_1007_s00415_022_11166_z springer_journals_10_1007_s00415_022_11166_z |
| PublicationCentury | 2000 |
| PublicationDate | 2022-09-01 |
| PublicationDateYYYYMMDD | 2022-09-01 |
| PublicationDate_xml | – month: 09 year: 2022 text: 2022-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
| PublicationTitle | Journal of neurology |
| PublicationTitleAbbrev | J Neurol |
| PublicationTitleAlternate | J Neurol |
| PublicationYear | 2022 |
| Publisher | Springer Berlin Heidelberg Springer Nature B.V |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
| References | Goldenberg (CR1) 2012; 37 Larochelle, Uphaus, Prat, Zipp (CR5) 2016; 39 Matias-Guiu, Cortés-Martínez, Valles-Salgado, Oreja-Guevara, Pytel, Montero, Moreno-Ramos, Matias-Guiu (CR6) 2017; 8 Carotenuto, Moccia, Costabile, Signoriello, Paolicelli, Simone, Lus, Brescia Morra, Lanzillo (CR10) 2019; 9 Pitteri, Romualdi, Magliozzi, Monaco, Calabrese (CR11) 2017; 23 Arnold, Piani-Meier, Bar-Or, Benedict, Cree, Giovannoni, Gold, Vermersch, Arnould, Dahlke, Hach, Ritter, Karlsson, Kappos, Fox (CR32) 2022 Benedict, Amato, DeLuca, Geurts (CR29) 2020; 19 Kappos, Bar-Or, Cree, Fox, Giovannoni, Gold, Vermersch, Arnold, Arnould, Scherz, Wolf, Wallstrom, Dahlke, Investigators (CR23) 2018; 391 Planche, Gibelin, Cregut, Pereira, Clavelou (CR8) 2016; 23 Dahlke, Arnold, Aarden, Ganjgahi, Haring, Cuklina, Nichols, Gardiner, Bermel, Wiendl (CR35) 2021; 27 CR30 Cree, Magnusson, Rouyrre, Fox, Giovannoni, Vermersch, Bar-Or, Gold, Piani Meier, Karlsson, Tomic, Wolf, Dahlke, Siponimod (CR34) 2022 Mannioui, Vauzanges, Fini, Henriet, Sekizar, Azoyan, Thomas, Pasquier, Giovannangeli, Demeneix, Lubetzki, Zalc (CR16) 2018; 24 Jaillard, Harrison, Stankoff, Aigrot, Calver, Duddy, Walsh, Pangalos, Arimura, Kaibuchi, Zalc, Lubetzki (CR15) 2005; 25 Ruano, Portaccio, Goretti, Niccolai, Severo, Patti, Cilia, Gallo, Grossi, Ghezzi, Roscio, Mattioli, Stampatori, Trojano, Viterbo, Amato (CR7) 2017; 23 Rovaris, Confavreux, Furlan, Kappos, Comi, Filippi (CR2) 2006; 5 Smith (CR27) 1982 Costa, Genova, DeLuca, Chiaravalloti (CR9) 2017; 23 Gentile, Musella, Bullitta, Fresegna, De Vito, Fantozzi, Piras, Gargano, Borsellino, Battistini, Schubart, Mandolesi, Centonze (CR18) 2016; 13 CR26 CR25 Ksiazek-Winiarek, Szpakowski, Glabinski (CR31) 2015; 2015 Lublin, Reingold, Cohen, Cutter, Sorensen, Thompson, Wolinsky, Balcer, Banwell, Barkhof, Bebo, Calabresi, Clanet, Comi, Fox, Freedman, Goodman, Inglese, Kappos, Kieseier, Lincoln, Lubetzki, Miller, Montalban, O'Connor, Petkau, Pozzilli, Rudick, Sormani, Stuve, Waubant, Polman (CR3) 2014; 83 Matloubian, Lo, Cinamon, Lesneski, Xu, Brinkmann, Allende, Proia, Cyster (CR14) 2004; 427 CR24 O'Sullivan, Schubart, Mir, Dev (CR17) 2016; 13 Bigaud, Rudolph, Briard, Beerli, Hofmann, Hermes, Muellershausen, Schubart, Gardin (CR19) 2021; 7 Kutzelnigg, Lucchinetti, Stadelmann, Bruck, Rauschka, Bergmann, Schmidbauer, Parisi, Lassmann (CR12) 2005; 128 CR22 CR21 Kremenchutzky, Rice, Baskerville, Wingerchuk, Ebers (CR4) 2006; 129 Benedict, DeLuca, Phillips, LaRocca, Hudson, Rudick (CR28) 2017; 23 Cree, Arnold, Fox, Gold, Vermersch, Benedict, Bar-Or, Piani-Meier, Rouyrre, Ritter, Kilaru, Karlsson, Giovannoni, Kappos (CR33) 2022 Gergely, Nuesslein-Hildesheim, Guerini, Brinkmann, Traebert, Bruns, Pan, Gray, Hinterding, Cooke, Groenewegen, Vitaliti, Sing, Luttringer, Yang, Gardin, Wang, Crumb, Saltzman, Rosenberg, Wallstrom (CR13) 2012; 167 Benedict, Tomic, Cree, Fox, Giovannoni, Bar-Or, Gold, Vermersch, Pohlmann, Wright, Karlsson, Dahlke, Wolf, Kappos (CR20) 2020; 96 BA Cree (11166_CR33) 2022 RHB Benedict (11166_CR29) 2020; 19 A Kutzelnigg (11166_CR12) 2005; 128 C Jaillard (11166_CR15) 2005; 25 C Larochelle (11166_CR5) 2016; 39 11166_CR24 11166_CR21 11166_CR22 JA Matias-Guiu (11166_CR6) 2017; 8 M Pitteri (11166_CR11) 2017; 23 L Ruano (11166_CR7) 2017; 23 M Rovaris (11166_CR2) 2006; 5 RH Benedict (11166_CR28) 2017; 23 MM Goldenberg (11166_CR1) 2012; 37 P Gergely (11166_CR13) 2012; 167 M Matloubian (11166_CR14) 2004; 427 L Kappos (11166_CR23) 2018; 391 DL Arnold (11166_CR32) 2022 11166_CR30 FD Lublin (11166_CR3) 2014; 83 DJ Ksiazek-Winiarek (11166_CR31) 2015; 2015 F Dahlke (11166_CR35) 2021; 27 SL Costa (11166_CR9) 2017; 23 A Smith (11166_CR27) 1982 A Gentile (11166_CR18) 2016; 13 M Kremenchutzky (11166_CR4) 2006; 129 11166_CR25 11166_CR26 RHB Benedict (11166_CR20) 2020; 96 V Planche (11166_CR8) 2016; 23 C O'Sullivan (11166_CR17) 2016; 13 M Bigaud (11166_CR19) 2021; 7 BA Cree (11166_CR34) 2022 A Carotenuto (11166_CR10) 2019; 9 A Mannioui (11166_CR16) 2018; 24 |
| References_xml | – year: 2022 ident: CR32 article-title: Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial publication-title: Mult Scler doi: 10.1177/13524585221076717 – volume: 23 start-page: 848 year: 2017 end-page: 854 ident: CR11 article-title: Cognitive impairment predicts disability progression and cortical thinning in MS: an 8-year study publication-title: Mult Scler doi: 10.1177/1352458516665496 – ident: CR22 – volume: 23 start-page: 721 year: 2017 end-page: 733 ident: CR28 article-title: Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis publication-title: Mult Scler doi: 10.1177/1352458517690821 – volume: 96 start-page: e376 year: 2020 end-page: e386 ident: CR20 article-title: Siponimod and cognition in secondary progressive multiple sclerosis: EXPAND secondary analyses publication-title: Neurology doi: 10.1212/WNL.0000000000011275 – volume: 23 start-page: 1258 year: 2017 end-page: 1267 ident: CR7 article-title: Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes publication-title: Mult Scler doi: 10.1177/1352458516674367 – volume: 2015 year: 2015 ident: CR31 article-title: Neural plasticity in multiple sclerosis: the functional and molecular background publication-title: Neural Plast doi: 10.1155/2015/307175 – volume: 129 start-page: 584 year: 2006 end-page: 594 ident: CR4 article-title: The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease publication-title: Brain doi: 10.1093/brain/awh721 – year: 1982 ident: CR27 publication-title: Symbol digit modalities test: manual – ident: CR30 – volume: 27 start-page: 2062 year: 2021 end-page: 2076 ident: CR35 article-title: Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): age is a key contributor to presentation publication-title: Mult Scler doi: 10.1177/1352458520988637 – volume: 37 start-page: 175 year: 2012 end-page: 184 ident: CR1 article-title: Multiple sclerosis review publication-title: P T – volume: 24 start-page: 1421 year: 2018 end-page: 1432 ident: CR16 article-title: The : an in vivo model to screen drugs favoring remyelination publication-title: Mult Scler doi: 10.1177/1352458517721355 – volume: 83 start-page: 278 year: 2014 end-page: 286 ident: CR3 article-title: Defining the clinical course of multiple sclerosis: the 2013 revisions publication-title: Neurology doi: 10.1212/WNL.0000000000000560 – volume: 25 start-page: 1459 year: 2005 end-page: 1469 ident: CR15 article-title: Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival publication-title: J Neurosci doi: 10.1523/JNEUROSCI.4645-04.2005 – volume: 391 start-page: 1263 year: 2018 end-page: 1273 ident: CR23 article-title: Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study publication-title: Lancet doi: 10.1016/S0140-6736(18)30475-6 – volume: 8 start-page: 643 year: 2017 ident: CR6 article-title: Functional components of cognitive impairment in multiple sclerosis: a cross-sectional investigation publication-title: Front Neurol doi: 10.3389/fneur.2017.00643 – volume: 128 start-page: 2705 year: 2005 end-page: 2712 ident: CR12 article-title: Cortical demyelination and diffuse white matter injury in multiple sclerosis publication-title: Brain doi: 10.1093/brain/awh641 – ident: CR25 – volume: 13 start-page: 207 year: 2016 ident: CR18 article-title: Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis publication-title: J Neuroinflammation doi: 10.1186/s12974-016-0686-4 – volume: 23 start-page: 282 year: 2016 end-page: 289 ident: CR8 article-title: Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis publication-title: Eur J Neurol doi: 10.1111/ene.12715 – ident: CR21 – volume: 39 start-page: 325 year: 2016 end-page: 339 ident: CR5 article-title: Secondary progression in multiple sclerosis: neuronal exhaustion or distinct pathology? publication-title: Trends Neurosci doi: 10.1016/j.tins.2016.02.001 – volume: 5 start-page: 343 year: 2006 end-page: 354 ident: CR2 article-title: Secondary progressive multiple sclerosis: current knowledge and future challenges publication-title: Lancet Neurol doi: 10.1016/S1474-4422(06)70410-0 – volume: 19 start-page: 860 year: 2020 end-page: 871 ident: CR29 article-title: Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues publication-title: Lancet Neurol doi: 10.1016/S1474-4422(20)30277-5 – year: 2022 ident: CR34 article-title: Disentangling disability and relapses in secondary progressive multiple sclerosis publication-title: Mult Scler J doi: 10.1177/1352458520971819 – volume: 427 start-page: 355 year: 2004 end-page: 360 ident: CR14 article-title: Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 publication-title: Nature doi: 10.1038/nature02284 – volume: 7 start-page: 20552173211049168 year: 2021 ident: CR19 article-title: Siponimod (BAF312) penetrates, distributes, and acts in the central nervous system: preclinical insights publication-title: Mult Scler J Exp Transl Clin – volume: 23 start-page: 772 year: 2017 end-page: 789 ident: CR9 article-title: Information processing speed in multiple sclerosis: past, present, and future publication-title: Mult Scler doi: 10.1177/1352458516645869 – volume: 167 start-page: 1035 year: 2012 end-page: 1047 ident: CR13 article-title: The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate publication-title: Br J Pharmacol doi: 10.1111/j.1476-5381.2012.02061.x – volume: 13 start-page: 31 year: 2016 ident: CR17 article-title: The dual S1PR1/S1PR5 drug BAF312 (siponimod) attenuates demyelination in organotypic slice cultures publication-title: J Neuroinflammation doi: 10.1186/s12974-016-0494-x – year: 2022 ident: CR33 article-title: Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: analysis of EXPAND core and extension data up to >5 years publication-title: Mult Scler doi: 10.1177/13524585221083194 – volume: 9 start-page: 18074 year: 2019 ident: CR10 article-title: Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis publication-title: Sci Rep doi: 10.1038/s41598-019-54153-7 – ident: CR26 – ident: CR24 – volume: 129 start-page: 584 year: 2006 ident: 11166_CR4 publication-title: Brain doi: 10.1093/brain/awh721 – volume: 5 start-page: 343 year: 2006 ident: 11166_CR2 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(06)70410-0 – volume: 23 start-page: 848 year: 2017 ident: 11166_CR11 publication-title: Mult Scler doi: 10.1177/1352458516665496 – volume: 83 start-page: 278 year: 2014 ident: 11166_CR3 publication-title: Neurology doi: 10.1212/WNL.0000000000000560 – volume: 23 start-page: 772 year: 2017 ident: 11166_CR9 publication-title: Mult Scler doi: 10.1177/1352458516645869 – volume: 9 start-page: 18074 year: 2019 ident: 11166_CR10 publication-title: Sci Rep doi: 10.1038/s41598-019-54153-7 – volume: 128 start-page: 2705 year: 2005 ident: 11166_CR12 publication-title: Brain doi: 10.1093/brain/awh641 – volume: 13 start-page: 31 year: 2016 ident: 11166_CR17 publication-title: J Neuroinflammation doi: 10.1186/s12974-016-0494-x – volume: 7 start-page: 205521732110491 year: 2021 ident: 11166_CR19 publication-title: Mult Scler J Exp Transl Clin – year: 2022 ident: 11166_CR34 publication-title: Mult Scler J doi: 10.1177/1352458520971819 – volume: 23 start-page: 1258 year: 2017 ident: 11166_CR7 publication-title: Mult Scler doi: 10.1177/1352458516674367 – volume: 167 start-page: 1035 year: 2012 ident: 11166_CR13 publication-title: Br J Pharmacol doi: 10.1111/j.1476-5381.2012.02061.x – volume: 24 start-page: 1421 year: 2018 ident: 11166_CR16 publication-title: Mult Scler doi: 10.1177/1352458517721355 – ident: 11166_CR22 – volume-title: Symbol digit modalities test: manual year: 1982 ident: 11166_CR27 – year: 2022 ident: 11166_CR32 publication-title: Mult Scler doi: 10.1177/13524585221076717 – ident: 11166_CR26 – ident: 11166_CR24 – volume: 13 start-page: 207 year: 2016 ident: 11166_CR18 publication-title: J Neuroinflammation doi: 10.1186/s12974-016-0686-4 – volume: 25 start-page: 1459 year: 2005 ident: 11166_CR15 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.4645-04.2005 – volume: 391 start-page: 1263 year: 2018 ident: 11166_CR23 publication-title: Lancet doi: 10.1016/S0140-6736(18)30475-6 – volume: 19 start-page: 860 year: 2020 ident: 11166_CR29 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(20)30277-5 – volume: 23 start-page: 282 year: 2016 ident: 11166_CR8 publication-title: Eur J Neurol doi: 10.1111/ene.12715 – volume: 23 start-page: 721 year: 2017 ident: 11166_CR28 publication-title: Mult Scler doi: 10.1177/1352458517690821 – volume: 27 start-page: 2062 year: 2021 ident: 11166_CR35 publication-title: Mult Scler doi: 10.1177/1352458520988637 – year: 2022 ident: 11166_CR33 publication-title: Mult Scler doi: 10.1177/13524585221083194 – ident: 11166_CR21 – volume: 39 start-page: 325 year: 2016 ident: 11166_CR5 publication-title: Trends Neurosci doi: 10.1016/j.tins.2016.02.001 – volume: 2015 year: 2015 ident: 11166_CR31 publication-title: Neural Plast doi: 10.1155/2015/307175 – ident: 11166_CR25 – volume: 8 start-page: 643 year: 2017 ident: 11166_CR6 publication-title: Front Neurol doi: 10.3389/fneur.2017.00643 – volume: 427 start-page: 355 year: 2004 ident: 11166_CR14 publication-title: Nature doi: 10.1038/nature02284 – volume: 37 start-page: 175 year: 2012 ident: 11166_CR1 publication-title: P T – ident: 11166_CR30 – volume: 96 start-page: e376 year: 2020 ident: 11166_CR20 publication-title: Neurology doi: 10.1212/WNL.0000000000011275 |
| SSID | ssj0008459 |
| Score | 2.4379737 |
| Snippet | Background
Siponimod is a sphingosine 1-phosphate receptor modulator approved for active secondary progressive multiple sclerosis (aSPMS) in most countries;... Siponimod is a sphingosine 1-phosphate receptor modulator approved for active secondary progressive multiple sclerosis (aSPMS) in most countries; however,... BackgroundSiponimod is a sphingosine 1-phosphate receptor modulator approved for active secondary progressive multiple sclerosis (aSPMS) in most countries;... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 5093 |
| SubjectTerms | Azetidines - pharmacology Azetidines - therapeutic use Benzyl Compounds - pharmacology Benzyl Compounds - therapeutic use Cognition Disease Progression Gadolinium Humans Lesions Magnetic Resonance Imaging Medicine Medicine & Public Health Multiple sclerosis Multiple Sclerosis - drug therapy Multiple Sclerosis, Chronic Progressive - diagnostic imaging Multiple Sclerosis, Chronic Progressive - drug therapy Multiple Sclerosis, Relapsing-Remitting - drug therapy NCT NCT01665144 Neurology Neuroradiology Neurosciences Original Communication Placebos Sphingosine 1-phosphate |
| SummonAdditionalLinks | – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELWgIMSF75aUggaJG0RKbCeOuVWlFRdWFQW0t2hiO9pIkKw220rsr2fsTYKWAhJcY8eJ7Znxs2bmDWOvcpkg3Y4xRnRVLHnq4qLmdGs1OW14ausCt8Um1GxWzOf6fEgK68do99ElGSz1lOzmqaF8NjGPST_zPN7cZLfouCt8wYaPF18m-1vIUCItETKJM5HJIVXm92PsHkfXMOb1UMlf_KXhGDq7_38TeMDuDbATjrdy8pDdcO0jdufD4Fh_zDYXzZK0-1tn4aqHEKhVddC0gMEeQu_vzRZX3yEEdPnYWXo6RiNCT4PS_Jr-LSAsu34Ni84ADoQn4HNYgJAmLBd0aIKA0_n58ewdBG7bJ-zz2emnk_fxUJYhNlLJdcxrgQQSCZrpOiFTL5IaUThhpRFGG-5BpVZW0EUQtdHKcGUtFxVH9PyGKPbZXtu17ikD7XKXqyqtuHWSWiudYlJossJa2EKZiKXj7pRm4Cz3pTO-lhPbcljUkha1DItabiL2enpnuWXs-Gvvo3HTy0F7-zI44zPCajxiL6dm0jvvTMHWdZfUJ1cERj29f8QOtjIyfU5khPtSrSKmdqRn6uA5vXdb2mYRuL21yIXIaMw3owz9_K0_z-Lw37o_Y3e5F8MQKnfE9tarS_ec3TZX66ZfvQja9AOvxhrC priority: 102 providerName: Springer Nature |
| Title | Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study |
| URI | https://link.springer.com/article/10.1007/s00415-022-11166-z https://www.ncbi.nlm.nih.gov/pubmed/35639197 https://www.proquest.com/docview/2700156432 https://www.proquest.com/docview/2672322600 https://pubmed.ncbi.nlm.nih.gov/PMC9363350 |
| Volume | 269 |
| WOSCitedRecordID | wos000803802100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1432-1459 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0008459 issn: 0340-5354 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BixAX3oVAqYzEDSwSO4ljLqjAVlxYrVpAe4sc29FGgiRstpXYX8_Y6021VPTCJVJix4k1D894xt8AvMrTWKF3rKhStqIpSywtaoZeq86R4ImpC7UpNiGm02I-l7Ow4TaEtMqtTvSK2nTa7ZG_9QHSDNdP9r7_RV3VKBddDSU0bsK-K5vt-FzMR4crLlJfLC3maUwznqXh0Iw_OueAptzZZEZR2vOcrncXpivW5tWkyb8ip35BOrn3v1O5D3eDKUqON7zzAG7Y9iHc_hKC7Y9gfdb0KPE_O0MuBuKTt6qONC1RXkeSwfnSRi1_E5_k5fJp8ek2Q5EMOCjOtBneEUX6bliRRaeJCiAoxJ1rIWh9kn6BCynhZDKfHU8_EY93-xi-nUy-fvxMQ6kGqlORriiruULDEc01Wceo_nlcK8UtN6nmWmrmDE0pDEfnUEkthWbCGMYrppTDPFT8APbarrVPgUib21xUScWMTbG1komKC4maWXJTCB1BsqVTqQOOuSun8aMcEZg9bUukbelpW64jeD2-029QPK7tfbilWxkkeigviRbBy7EZZdEFWFRru3Pskws0UB3kfwRPNtwyfo5naAsmUkQgdvho7OBwvndb2mbh8b4lzznPcMw3W467_K1_z-LZ9bN4DneY436fLncIe6vluX0Bt_TFqhmWR16O_LU4gv0Pk-nsFO9Oz77_AS4CJ30 |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgigX3o9AASPBCSwSOxvHSAhVtFWrtqtKFGlvqeM42kglCZttUfdH8RsZO49qqeitB66x48TJ53nYM98AvI1CX6F3rKhSJqUhCwyNc4Zeq47whwdZHqu22IQYj-PJRB6uwO8-F8aGVfYy0QnqrNJ2j_yjOyAdof5kX-qf1FaNsqerfQmNFhZ75vwXumzN591N_L_vGNveOvq6Q7uqAlSHIpxTlnOFNg5aFjL3UVJxP1eKG56FmmupmbWJpMg4-jFKaik0E1nGeMqUsvR8iuO4N-AmynFhnT0xGRw8Pw5dcTafhz4d8VHYJem4VD1LbGVzoRlF6RJFdLGsCC9Zt5eDNP86qXUKcPve__bp7sPdztQmG-3aeAArpnwItw-6YIJHsPhW1CjRflQZOWuIC05LK1KURDkdQBq7V5Cp2TlxQWw2Xhiv9hGYpMFB8csWzSeiSF01czKtNFEdyQuxeTsErWtST9FQIJxsTQ43xpvE8fk-hu_XMvMnsFpWpXkGRJrIRCINUpaZEFtTGSg_lqh5JM9ioT0IelwkuuNpt-VCTpKBYdphKUEsJQ5LycKD98M9dctScmXv9R4nSSexmuQCJB68GZpR1tgDJFWa6hT7RAINcFvSwIOnLTqHx_ER2rqBFB6IJdwOHSyP-XJLWUwdn7nkEecjHPNDj_CL1_r3LJ5fPYvXsLZzdLCf7O-O917AHWZXngsNXIfV-ezUvIRb-mxeNLNXbg0TOL5u5P8B7-h_uA |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD4aHZp44X4pDDASPEG0xE7iGAmhQVsxDaKKi9S3zHEctRIkoemG1p_Gr-PYuUxlYm974LV2nDr5fM7n-JzvADwPfVfi7lg6UurU8amnnSinuGtVIb5wL8sj2RSb4HEczWZiugW_u1wYE1bZ2URrqLNSmW_ke_aANED_SffyNixiOpq8rX46poKUOWntymk0EDnUp79w-1a_ORjhu35B6WT89f0Hp60w4Cif-yuH5kwi30GWIXIXrRZzcymZZpmvmBKKGn4keMZwTyOFElxRnmWUpVRKI9UnGY57BbY5kgx_ANvvxvH0c-8HIt-WanOZ7zoBC_w2Zccm7hmZK5MZTR20NWHorDfd4jmuez5k869zW-sOJzf-5wd5E663JJzsN6vmFmzp4jbsfGrDDO7A-suiQlv3o8zISU1s2FpakkVBpPUOpDZfETK5PCU2vM1EEuOvXWwmqXFQfMqL-jWRpCrrFZmXishW_oWYjB6CvJtUc6QQhJHxbLofj4hV-r0L3y5l5vdgUJSFfgBE6FCHPPVSmmkfW1PhSTcS6JMEyyKuhuB1GElUq-BuCol8T3rtaYurBHGVWFwl6yG87K-pGv2SC3vvdphJWltWJ2eAGcKzvhmtkDlakoUuj7FPyJGam2IHQ7jfILW_HQuQBXuCD4FvYLjvYBTON1uKxdwqnQsWMhbgmK86tJ_9rX_P4uHFs3gKOwj45ONBfPgIrlGzCG3M4C4MVstj_RiuqpPVol4-aRc0gaPLhv4fYK2J2A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Siponimod+vs+placebo+in+active+secondary+progressive+multiple+sclerosis%3A+a+post+hoc+analysis+from+the+phase+3+EXPAND+study&rft.jtitle=Journal+of+neurology&rft.au=Gold%2C+Ralf&rft.au=Piani-Meier%2C+Daniela&rft.au=Kappos%2C+Ludwig&rft.au=Bar-Or%2C+Amit&rft.date=2022-09-01&rft.pub=Springer+Nature+B.V&rft.issn=0340-5354&rft.eissn=1432-1459&rft.volume=269&rft.issue=9&rft.spage=5093&rft.epage=5104&rft_id=info:doi/10.1007%2Fs00415-022-11166-z&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0340-5354&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0340-5354&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0340-5354&client=summon |